Sugi Predict

Sugi Predict / Compounds / SCHEMBL112489

SCHEMBL112489

SCHEMBL112489

CCOC(=O)[C@@H](CS)NC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ KMT2A Q03164 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ CAD P27708 1/20 0.42
▸ MGAM O43451 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ SI P14410 1/20 0.41
▸ MGAM2 Q2M2H8 1/20 0.41
▸ CPB2 Q96IY4 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.39
▸ ALOX15 P16050 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ PTGS2 P35354 1/20 0.38
▸ THPO P40225 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL120529 1.00 L3MBTL1 (0.46) L3MBTL1KMT2APOLBCADMGAM
SCHEMBL120528 1.00 L3MBTL1 (0.46) L3MBTL1KMT2APOLBCADMGAM
Hydrochloric Acid SCHEMBL6315039 0.98 L3MBTL1 (0.44) L3MBTL1KMT2APOLBCADMGAM
Hydrochloric Acid SCHEMBL6322812 0.98 L3MBTL1 (0.44) L3MBTL1KMT2APOLBCADMGAM
Bromide SCHEMBL8314221 0.98 L3MBTL1 (0.44) L3MBTL1KMT2APOLBCADMGAM
Bromide SCHEMBL8314219 0.98 L3MBTL1 (0.44) L3MBTL1KMT2APOLBCADMGAM
SCHEMBL113196 0.83 KDM4E (0.35) L3MBTL1KMT2APOLBALDH1A1ALOX15
SCHEMBL10674538 0.83 L3MBTL1 (0.43) L3MBTL1KMT2APOLBCADMGAM
SCHEMBL8681998 0.82 — —
SCHEMBL110065 0.82 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100278905-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER ABBVIE INC. 2010-11-04 — — US claimed
CN-122059859-A Synthesis method of diaryl methyl sulfide under biocompatible condition 南京工业大学 2026-05-19 — — CN disclosed
US-20170196985-A1 SULFUR(VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF THE SCRIPPS RESEARCH INSTITUTE 2017-07-13 — — US disclosed
US-8927009-B2 ABT-263 capsule ABBVIE INC. (US) 2015-01-06 — — US disclosed
US-8728516-B2 Stabilized lipid formulation of apoptosis promoter ABBVIE INC. (US) 2014-05-20 — — US disclosed
US-8513243-B2 ABT-263 crystalline forms ABBVIE INC. (US) 2013-08-20 — — US disclosed
US-8362013-B2 Salt of ABT-263 and solid-state forms thereof ABBVIE INC. (US) 2013-01-29 — — US disclosed
US-8362014-B2 ABT-263 crystalline forms ABBVIE INC. (US) 2013-01-29 — — US disclosed
EP-2515883-A1 ABT-263 CAPSULE Abbott Laboratories (US) 2012-10-31 — — EP disclosed
EP-2477972-A1 ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR USE IN TREATING BCL-2 PROTEIN RELATED DISEASES Abbott Laboratories (US) 2012-07-25 — — EP disclosed
US-20110159085-A1 ABT-263 CAPSULE ABBOTT LABORATORIES (US) 2011-06-30 — — US disclosed
WO-2011079127-A1 ABT-263 CAPSULE ABBOTT LABORATORIES (US) 2011-06-30 — — WO disclosed
WO-2011034934-A1 ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR USE IN TREATING BCL-2 PROTEIN RELATED DISEASES ABBOTT LABORATORIES (US) 2011-03-24 — — WO disclosed
US-20110071151-A1 ABT-263 CRYSTALLINE FORMS ABBOTT LABORATORIES (US) 2011-03-24 — — US disclosed
WO-2010147899-A1 STABLE NANOPARTICULATE DRUG SUSPENSION ABBOTT LABORATORIES (US) 2010-12-23 — — WO disclosed
US-20100323020-A1 STABLE NANOPARTICULATE DRUG SUSPENSION ABBOTT LABORATORIES (US) 2010-12-23 — — US disclosed
US-20100305125-A1 SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF ABBVIE INC. 2010-12-02 — — US disclosed
US-20100297194-A1 FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER ABBOTT LABORATORIES 2010-11-25 — — US disclosed
US-20100278905-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER ABBVIE INC. 2010-11-04 — — US disclosed
WO-2010127190-A1 SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF ABBOTT LABORATORIES (US) 2010-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170196985-A1 SULFUR(VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF CYP2F1, NAF1, CYP2S1 L3MBTL1 4222/4885KMT2A 2082/4885POLB 2700/4885
US-20100323020-A1 STABLE NANOPARTICULATE DRUG SUSPENSION BCL2L10, TMBIM6, BCOR L3MBTL1 479/4885KMT2A 3879/4885POLB 2867/4885
US-20100297194-A1 FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER BCL2, BAX, BCL2L2 L3MBTL1 278/4885KMT2A 2758/4885POLB 1068/4885
US-20110071151-A1 ABT-263 CRYSTALLINE FORMS BCL3, BCL2, BCL2L13 L3MBTL1 307/4885KMT2A 1456/4885POLB 2196/4885
US-20100305125-A1 SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF BCL3, BCL2, BCL2L13 L3MBTL1 134/4885KMT2A 1270/4885POLB 2023/4885
US-20100278905-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER BCL2, BAX, BCOR L3MBTL1 375/4885KMT2A 2887/4885POLB 1608/4885
US-20110159085-A1 ABT-263 CAPSULE BCL2, BCL2L13, BCL2L10 L3MBTL1 1173/4885KMT2A 2968/4885POLB 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.